Italy Moves to Rein in Pharmaceutical costs with New Price Renegotiation Mechanism
Table of Contents
Italy is poised to implement a new system for automatically renegotiating drug prices, aiming to curb escalating pharmaceutical spending and expand access to innovative therapies. The initiative, spearheaded by the Italian Medicines Agency (Aifa), comes as the nation grapples with an aging population and the rising costs associated with advanced treatments.
A recent example illustrates the urgency: “a drug grows rapidly, then doubles in two years: from an average value of 1.5 million euros it rises to 3,” a senior official stated. “To lower them through discounts that are triggered precisely on the basis of the profits that companies have on a particular product. The higher they are, the more valuable the discount is.”
Beyond Spending Caps: Addressing the root of the Problem
According to Aifa‘s president, simply raising the spending ceiling is not a enduring solution. “It is not a problem of the ceiling. That will never be enough: the more it is raised,the more the spending will grow,” he explained. The core issue, he argues, lies in demographic trends and a cultural preference for reactive treatment over proactive prevention. Italy’s aging population is a meaningful driver of increased medicine consumption, straining the nation’s universal healthcare system.
The agency is advocating for a two-pronged approach: increasing the appropriateness of prescriptions and prioritizing preventative care. “Treatment is a right, but prevention must be a citizen’s duty,” the president emphasized. “There are many pathologies that can be avoided with correct lifestyles. Prevention is truly essential, it should also be taught in school.”
The Evolving Landscape of Pharmacology
The shift in pharmacological focus – from symptom management to addressing the underlying mechanisms of disease – is also impacting costs. The emergence of advanced therapies like Car-T gene therapy, while offering potential cures, comes with a considerable price tag. However, the president noted that these treatments can ultimately generate savings by resolving chronic conditions. “
Recent changes in the distribution of anti-diabetes drugs,specifically the transition to pharmacy purchasing,have sparked debate among regional authorities due to increased expenditure. The Aifa president clarified that the new system is mandated by state regulation. He also highlighted accomplished negotiations with manufacturers, citing the example of gliflozines, where favorable pricing was secured. “With the new system there can be a better distribution of the medicines and therefore a greater adherence to therapies by patients,” he said. A monitoring table is currently operational to assess the impact of these changes.
Expanding Access to Obesity Therapies – A Cautious Approach
Access to new anti-obesity drugs remains a contentious issue. Currently,reimbursement is limited to specific therapeutic indications. The Aifa president cautioned against broad access, emphasizing potential side effects and the need for lifestyle changes. “We shouldn’t think that they will solve everything on their own, the patient must also change his lifestyle.”
However, an expansion of eligibility criteria is under consideration. Potential extensions could include very obese, non-diabetic individuals, or those with weight-related cardiac complications. “But the drugs will not become the responsibility of the State for those who take them onyl as they are overweight,” the president affirmed.
Internal Disputes Resolved, Focus Remains on Core Mission
The agency recently addressed a public disagreement between its administrative and scientific directors, prompting a request for clarification from the Minister of Health, Orazio Schillaci.The president confirmed that a report has been submitted and that a collaborative working environment has been restored. “In the meantime we have returned to work in a calm and collaborative climate. We are doing a lot in this period. Of course, there are moments of even heated confrontation, but the sense of responsibility for our important function remains alive in all of us.”
The agency remains committed to navigating the complex challenges of pharmaceutical spending while ensuring access to essential and innovative treatments for Italian citizens.
